Description
Release form
Injectable solution tan, clear.
Pharmacological action
Nootropic drug.
Cerebrolysin contains low molecular weight biologically active neuropeptides that penetrate the BBB and directly enter the nerve cells. The drug has an organ-specific multimodal effect on the brain, i.e. provides metabolic regulation, neuroprotection, functional neuromodulation and neurotrophic activity.
Metabolic regulation: Cerebrolysin increases the efficiency of aerobic energy metabolism of the brain, improves intracellular protein synthesis in the developing and aging brain.
Neuroprotection: the drug protects neurons from the damaging effects of lactic acidosis, prevents the formation of free radicals, increases survivability and prevents the death of neurons under conditions of hypoxia and ischemia, reduces the damaging neurotoxic effect of excitatory amino acids (glutamate).
Neurotrophic activity: Cerebrolysin is the only nootropic peptidergic drug with proven neurotrophic activity similar to the action of natural factors of neuronal growth (NGF), but manifested under conditions of peripheral administration.
Functional neuromodulation: the drug has a positive effect on cognitive impairment in memory processes.
in children
– attention deficit disorder in children
– endogenous depression resistant to antidepressants (in Stave complex therapy).
Contraindications
– severe renal failure
– status epilepticus
– hypersensitivity to the drug.
With caution, the drug should be prescribed for allergic diathesis, epileptic diseases, including with generalized epilepsy, due to a possible increase in the frequency of seizures.
Use during pregnancy and lactation
Cerebrolysin should be used during pregnancy and during breastfeeding only after a careful analysis of the relationship between the positive treatment effect and risk associated with its conduct.
The results of experimental studies do not suggest that Cerebrolysin has any teratogenic effect or has a toxic effect on the fetus. However, no similar clinical studies have been conducted.
Special instructions
If the injections are too fast, you may feel hot, sweating, or dizzy. Therefore, the drug should be administered slowly.
The compatibility of the drug (within 24 hours at room temperature and with light) was checked and confirmed with the following standard solutions for infusion: 0.9% sodium chloride solution, Ringer’s solution, 5% solution of dextrose (glucose).
The simultaneous use of the drug Cerebrolysinum with vitamins and drugs that improve cardiac circulation, but these drugs should not be mixed in the same syringe with Cerebrolysinum.
Use only a clear solution of Cerebrolysin and only once.
Influence on the ability to drive vehicles and control mechanisms
Clinical studies have shown that Cerebrolysin does not affect the ability to drive vehicles and use mechanisms.
Composition
1 ml – cerebrolysin concentrate (a complex of peptides * obtained from the pig brain) 215.2 mg
* molecular weight not more than 10,000 daltons.
Dosage and administration
The drug is administered parenterally. The dose and duration of use depend on the nature and severity of the disease, as well as on the age of the patient. A single administration of the drug in a dose of up to 50 ml is possible, however, a course of treatment is more preferable.
The recommended course of treatment is daily injections for 10-20 days.
Indication Dose
Acute conditions (ischemic stroke, traumatic brain injury, complications of neurosurgical operations) from 10 ml to 50 ml
In the residual period of stroke and traumatic damage to the brain and spinal cord from 5 ml to 50 ml
Psychoorganic syndrome 5 ml and depression 30 ml
Alzheimer’s disease, vascular and combined Alzheimer-vascular dementia from 5 ml to 30 ml
In neuropediatric practice 0.1-0.2 ml / kg body weight
Repeated courses can be taken to improve the treatment until an improvement in the patient’s condition due to treatment is observed. After the first course, the frequency of injections can be reduced to 2 or 3 times a week.
Cerebrolysin is used parenterally in the form of a / m injection (up to 5 ml) and an iv injection (up to 10 ml). The drug in a dose of 10 ml to 50 ml is recommended to be administered only by slow intravenous infusion after dilution with standard solutions for infusion. The duration of infusion is from 15 to 60 minutes.
Side effects
The frequency of adverse reactions was determined in accordance with WHO recommendations: very often: (? 1/10) often: (from? 1/100 to <1/10) infrequently (from? 1/1000 to <1/100 ) rarely (from? 1/10,000 to <1/1000) very rarely, including single messages (<1/10 000). From the side of the immune system: very rarely – increased individual sensitivity, allergic reactions. Mental disorders: rarely – the expected effect of activation is accompanied by excitement, manifested aggressive behavior, confusion, insomnia. From the nervous system: rarely – too fast administration of the drug can lead to dizziness very rarely – isolated cases of generalized epilepsy and one case of seizures have been associated with cerebrolysin. On the part of the cardiovascular system: very rarely – too fast administration of the drug can lead to increased heart rate and arrhythmia. From the digestive system: very rarely – dyspepsia, diarrhea, constipation, nausea, vomiting rarely – loss of appetite. On the part of the skin and subcutaneous tissues: very rarely – skin reactions are rare – with excessively fast administration, a sensation of fever, sweating, and itching are possible. General disorders and disorders at the injection site: very rarely – redness, itching, burning at the injection site, pain in the neck, head and extremities, fever, mild back pain, shortness of breath, chills, collapse state. According to the results of one study, the association between the use of the drug in rare cases (from> 1/10,000 to <1/1000) with hyperventilation, arterial hypertension, hypotension, fatigue, tremor, the possible development of depression, apathy and / or drowsiness, flu-like was reported symptoms (common cold, cough, respiratory tract infection). Since cerebrolysin is used mainly in elderly patients, the above symptoms of diseases are typical for this age group and often also occur without taking the drug. It should be noted that some undesirable effects (agitation, arterial hypertension, arterial hypotension, lethargy, tremor, depression, apathy, dizziness, headache, shortness of breath, diarrhea, nausea) were detected during clinical trials and occurred equally in patients , receiving Cerebrolysin, and in patients of the placebo group. If any of the side effects indicated in the instructions are aggravated or any other side effects not listed in the instructions are noted, the patient should inform the attending physician. Notification in case of suspected side effects It is important to report side effects after registration of the drug in order to ensure continuous monitoring of the risk-benefit ratio of the drug. Medical workers are asked to report all cases of side effects observed when using the drug through national reporting systems for adverse reactions and / or to the address of the company s representative. Drug Interactions Given the pharmacological profile of the drug Cerebrolysin, particular attention should be paid to possible additive effects when given together with antidepressants or MAO inhibitors. In such cases, it is recommended to reduce the dose of antidepressant. The use of the drug Cerebrolysin in high doses (30-40 ml) in combination with MAO inhibitors in high doses can cause an increase in blood pressure. Do not mix Cerebrolysin and balanced amino acid solutions in the same infusion solution. Cerebrolysin is incompatible with solutions that include lipids and with solutions that change the pH of the medium (5.0-8.0). Overdose Cerebrolysin overdose has not been reported. Storage conditions not higher than 25 ° C. Expiration Expiration of the preparation in ampoules – 5 years, in vials – 4 years. Do not use after the expiry date stated on the packaging. active substance Peptides brain complex prescription from pharmacies Prescription lekarstvennaja form Solution for
